[EN] FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY [FR] DÉRIVÉS D'IMIDAZOLE TRICYCLIQUES FUSIONNÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF
[EN] FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY [FR] DÉRIVÉS D'IMIDAZOLE TRICYCLIQUES FUSIONNÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF
FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
申请人:UCB Biopharma SPRL
公开号:EP3080114A1
公开(公告)日:2016-10-19
Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity
申请人:UCB BIOPHARMA SPRL
公开号:US20160304530A1
公开(公告)日:2016-10-20
A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4′,3′:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c′]dipyridine, dihydro-1H-pyrano[3′,4′:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.